Exposure

Treatment exposure

Approximately one third of patients were able to stay on YONDELIS^® 6 cycles or longer

1 out of 3 (34%) patients in the YONDELIS^® group received 6 or more cycles of treatment, and 1 out of 10 (10%) received 12 or more cycles.¹

Cumulative treatment cycles received (all treated patients)²
Treatment cycles received	YONDELIS^® (n=340) % (n)	Dacarbazine (n=155) % (n)
≥3	57.1 (194)	43.2 (67)
≥6	34.4 (117)	17.4 (27)
≥9	17.4 (59)	5.2 (8)
≥12	10.3 (35)	1.9 (3)

Cumulative treatment cycles received (All treated patients)²
Treatment cycles received	YONDELIS^® (n=340) % (n)
≥3	57.1 (194)
≥6	34.4 (117)
≥9	17.4 (59)
≥12	10.3 (35)
Treatment cycles received	Dacarbazine (n=155) % (n)
≥3	43.2 (67)
≥6	17.4 (27)
≥9	5.2 (8)
≥12	1.9 (3)

References:

Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34(8):786-793.
Demetri GD, von Mehren M, Jones RL, et al. Patient-reported outcomes from randomized, phase 3 study of trabectedin vs dacarbazine in advanced leiomyosarcoma or liposarcoma. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 3-7, 2016; Chicago, IL.